OptimizeRx (OPRX) Common Equity (2010 - 2026)

OptimizeRx has disclosed Common Equity across 17 years of filings, most recently posting $131.1 million for Q2 2026.

• In Q2 2026, Common Equity rose 9.89% year-over-year to $131.1 million; the TTM figure through Jun 2026 stood at $131.1 million (up 9.89% YoY), while the FY2025 annual figure was $128.3 million, up 9.65% from the prior year.
• Common Equity came in at $131.1 million for Q2 2026 at OptimizeRx, up from $129.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $140.8 million in Q2 2022 to a low of $114.5 million in Q3 2024.
• Average Common Equity over 5 years is $124.0 million, with a median of $123.3 million recorded in 2023.
• Year-over-year, Common Equity gained 12.95% in 2022 and dropped 17.76% in 2023.
• Over 5 years, Common Equity stood at $126.1 million in 2022, then gained by 0.35% to $126.6 million in 2023, then declined by 7.55% to $117.0 million in 2024, then grew by 9.65% to $128.3 million in 2025, then rose by 2.17% to $131.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $131.1 million in Q2 2026, $129.6 million in Q1 2026, and $128.3 million in Q4 2025.